Large Outflow of Money Witnessed in St. Jude Medical

St. Jude Medical (STJ) : The total negative money flow of $16.04 million on Tuesday indicates selling on strength. The inflow of money on upticks was $24.82 million, compared to $40.86 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.61. The negative money flow of $14.17 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $14.17 million. The price action in the St. Jude Medical (STJ) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $80.88 with a gain of $0.21 , a change of 0.26% over the previous days close. The stock registered 0.37% for the week.


The company Insiders own 4.8% of St. Jude Medical shares according to the proxy statements. Institutional Investors own 85.55% of St. Jude Medical shares. In an insider trading activity, The Securities and Exchange Commission has divulged that Fecho Jeff, officer (VP, Global Quality) of St Jude Medical Inc, had unloaded 10,408 shares at an average price of $51.71 in a transaction dated on February 5, 2016. The total value of the transaction was worth $538,198.

Shares of St. Jude Medical Inc. rose by 3.52% in the last five trading days and 4.99% for the last 4 weeks. St. Jude Medical Inc. is up 41.24% in the last 3-month period. Year-to-Date the stock performance stands at 32.23%.

St. Jude Medical (NYSE:STJ): stock turned positive on Tuesday. Though the stock opened at $80.75, the bulls momentum made the stock top out at $81.21 level for the day. The stock recorded a low of $80.68 and closed the trading day at $80.88, in the green by 0.26%. The total traded volume for the day was 2,007,320. The stock had closed at $80.67 in the previous days trading.

St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker systems, atrial fibrillation (AF) products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, heart failure monitoring device and other vascular accessories), structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.